Actively Recruiting
First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults Aged 18 to 60 with Charcot-Marie-Tooth Disease Type 1A
Led by Novartis Pharmaceuticals · Updated on 2026-07-29
28
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and how the body processes EDK060 compared to a placebo in adults with Charcot-Marie-Tooth Disease Type 1A CMT1A. This Phase 1 study aims to understand the effects of different doses of EDK060 in this patient group. The study is sponsored by Novartis Pharmaceuticals and involves randomized and blinded treatment assignments to ensure reliable results. Participants will receive a single dose of EDK060 or a matching placebo through an intravenous infusion. There are four dose levels of EDK060 being tested, labeled as doses A, B, C, and D. The study uses a parallel group design where each participant is assigned to one treatment group and monitored accordingly. During the study, participants will be monitored from baseline up to day 140 for any adverse events and serious adverse events to assess safety. Blood samples will be taken to measure how EDK060 behaves in the body, including peak concentrations and timing. The study will also check tolerability and collect other relevant health information throughout this period. Overall participation lasts several months, allowing for thorough assessment of the drugs effects.
CONDITIONS
Brief Title
A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here